Replies to post #157631 on Innovation Pharmaceuticals Inc (IPIX)

[someconcerns]

Karin,

In the case of Cellceutix's drugs, I believe we should have a better than average chance of advancing to the next Phase in each compound because of how sharp Menon is in interpreting the data and deciding what compounds should advance at what dosages. All IMHO, of course.

[loanranger]

"Prurisol ph II and Brilacidin ph IIb ABSSSI were both successful. Two out of two completed ph II's successful."
The term "successful" needs to be a bit more definitive when used in a statistical measurement.

I think this is how the study defined it:
"Phase transitions occur when a drug candidate advances into the next phase of development or is suspended by the sponsor."

[frrol]

Struck me too but then these are conditional probabilities and the last stage (Phase 3) is also the most expensive, so it actually makes sense: you'd want to winnow out the "unpromising" therapy at the earliest test of efficacy.

I too am impressed with our Phase 2 successes. Looking forward to Kevetrin to see if we keep up the streak.